Previous 10 | Next 10 |
On Wednesday, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported first-quarter results that showed impressive sales growth for its recently launched drugs. Unfortunately, the COVID-19 pandemic has watered down the launch of its lead drug, Onpattro, and the company isn't quite as confident ...
Vir and Alnylam Go Ahead with COVID-19 Gene Silencing Therapy Vir Biotechnology ( VIR ) announced a new COVID-19 drug candidate, VIR-2703. The company is collaborating with Alnylam Pharmaceuticals ( ALNY ) for developing this treatment which is an inhalable RNAi therapeutic which works by ...
Alnylam Pharmaceuticals ( ALNY ) Q1 results : More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q1 Non-GAAP EPS of -$1.52 misses by $0.01 ; GAAP EPS of -$1.62 beats by $0.25 . More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
− Achieved First Quarter 2020 ONPATTRO ® Net Product Revenues of $66.7 Million with More Than 950 Patients on Commercial Product Worldwide – − Achieved First Quarter 2020 GIVLAARI ® Net Product Revenues of $5.3 Million with More Than 50 Patients on Comm...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) is scheduled to announce Q1 earnings results on Wednesday, May 6th, before market open. The consensus EPS Estimate is -$1.51 (-6.3% Y/Y) and the consensus Revenue Estimate is $90.45M (+171.7% Y/Y). Over the last 2 years, ALNY has beaten EPS esti...
The collaboration between Vir Biotechnology (NASDAQ: VIR) and Alnylam (NASDAQ: ALNY) that they expanded in March to address COVID-19 has selected a treatment candidate to advance into clinical trials. The partners will seek accelerated approval from regulators to treat h...
Vir Biotechnology (NASDAQ: VIR ) and collaboration partner Alnylam Pharmaceuticals (NASDAQ: ALNY ) announce a new COVID-19 candidate, VIR-2703, an inhalable RNAi therapeutic that targets the SARS-CoV-2 genome for the potential treatment and/or prevention of the respiratory illness. More ...
− Highly Potent and Broadly Cross-Reactive RNAi Therapeutic Development Candidate Selected Only Three Months After Program Initiation − − Companies Expect to Start Human Clinical Trials at or Around Year-End 2020 – Vir Biotechnology, Inc. (Nasdaq: VIR) ...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...